RecruitingPHASE1, PHASE2NCT04819841

Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease

Studying Genetic hemoglobinopathy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Kamau Therapeutics
Principal Investigator
Mathew Porteus, MD, PhD
Kamau Therapeutics
Intervention
nula-cel Drug Product(genetic)
Enrollment
15 enrolled
Eligibility
12-40 years · All sexes
Timeline
20212028

Study locations (4)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04819841 on ClinicalTrials.gov

Other trials for Genetic hemoglobinopathy

Additional recruiting or active studies for the same condition.

See all trials for Genetic hemoglobinopathy

← Back to all trials